Bristol Myers Squibb Shares Cross 6% Yield Mark
In trading on Wednesday, shares of Bristol Myers Squibb were yielding above the 6% mark based on its quarterly dividend (annualized to $2.4), with the stock changing hands as low as $39.94 on the d...
This Unpopular Dividend Stock Is a Buy
High-yield dividend stocks, on balance, are incredible value creators for long-term investors. Bristol Myers Squibb's yield has swelled to 5.6% this year, creating a compelling opportunity for pati...
Bristol Myers (BMY) Updates Action Date for Subcutaneous Opdivo
The FDA assigns a new target action date of Dec 29, 2024, to Bristol Myers (BMY) BLA for subcutaneous nivolumab (nivolumab and hyaluronidase).
NeoPhore closes oversubscribed Series B extension round with additional funding from Bristol Myers Squibb
Additional funding will be used to explore novel biology around the MMR pathway and accelerate progression of the lead program into candidate selection LONDON , May 22, 2024 /PRNewswire/ -- NeoPhor...
Insider Trading is Good News for These Stocks
Insiders are buying these hot stocks that have ample upside for investors. The list includes pharma, entertainment, and financial stocks and Berkshire buys.
Bristol Myers (BMY) Gets FDA Nod for Breyanzi Label Expansion
Bristol Myers Squibb (BMY) obtains FDA approval for the label expansion of CAR T cell therapy Breyanzi to treat adult patients with relapsed or refractory follicular lymphoma.
Bristol-Myers Squibb Company (BMY) Bank of America Global Healthcare Conference 2024 Transcript
Bristol-Myers Squibb Company (NYSE:BMY ) Bank of America Global Healthcare Conference 2024 May 15, 2024 2:20 PM ET Company Participants David Elkins – Executive Vice President and Chief Financial O...
US FDA approves expanded use of Bristol's cancer cell therapy
The U.S. Food and Drug Administration on Wednesday approved the expanded use of Bristol Myers Squibb's cancer cell therapy Breyanzi to include the treatment of adults with a type of blood cancer th...
Dividend Capture Captains: The 3 Best Blue-Chip Stocks for Tactical Traders
Give someone a dividend and you pay them that day but teach them to capture the dividend and you provide investment income for life! Executing a capture-the-dividend trade entails buying the stock ...
Bristol-Myers Squibb dragged down the S&P 500 this earnings season
More than 90% of the companies in the S&P 500 (^GSPC) have reported their earnings for the first quarter of 2024, which yielded a mostly strong result for the index. However, Bristol-Myers Squibb (...
Bristol-Myers Squibb Company (BMY) Presents at Guggenheim Securities Radiopharmaceuticals Day (Transcript)
Bristol-Myers Squibb Company. (NYSE:BMY ) Guggenheim Securities Radiopharmaceuticals Day May 13, 2024 11:00 AM ET Company Participants Ben Hickey - President RayzeBio, Head of Mirati Conference Cal...
Bristol Myers (BMY) Fails to Meet Goal in Opdivo NSCLC Study
Bristol Myers' (BMY) late-stage label-expanding study evaluating the Opdivo/Yervoy combination fails to meet the primary endpoint of progression-free survival in unresectable stage III NSCLC.
Down but Not Out: 3 Stocks to Buy on a Post-Earnings Dip
Starbucks is still seeing strong traffic, despite its earnings miss. Datadog's longer-term prospects look better than its short-term hiccup.
Is Bristol Myers' Dividend in Danger?
Expenses related to acquisitions recently weighed down Bristol Myers' earnings results. The company, however, still generates strong free cash flow.
Related Companies